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Abstract
“Between January 1998 and March 2000, veterinarians at the ASPCA National Animal
Poison Control Center (NAPCC) consulted on more than 1,050 cases of accidental exposures to
acetaminophen and 1,100 cases of ibuprofen ingestion in dogs and cats” (Richardson, 2000).
NSAID toxicity has become an increasingly common occurrence in small companion
animals within the last decade due to widespread usage (Zhou, Boudreau, & Freedman, 2014).
Depending on the specific drug, treatment is centered around early decontamination and
prevention of kidney and hepatic damage, and methemoglobanemia. Currently,
methemoglobanemia is treated with intravenous delivery of methylene blue and less commonly
through oral administration. While these methods have been shown to be successful, congenital
forms of methemoglobinemia are more difficult to manage as reoccurring treatments are
imperative.
A biocompatible hydrogel composed of Pluronic F127 and methylene blue was created at
various percent weight ratios to analyze release kinetics and determine the most effective
composition for clinical treatment of methemoglobinemia. Using a hydrogel for localized
delivery of methylene blue allows for long-term release of the drug, making treatment more
feasible for affected patients and their owners.
Initially, samples were created using 15-20 percent weight Pluronic F127 and deionized
water in 20 mL vials. The polymer was allowed to dissolve by mechanical stirring using a
magnetic stir bar for 24 hours. Once completely dissolved, 7.8%, 15.6%, or 31.2% methylene
blue was added to each vial. Samples were placed in an oven at 37 degrees Celsius. Samples
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were observed on 60-second intervals to check for gel formation. At this critical point, the
solution was no longer viscous. Clinically favorable samples achieved a gel formation time at
less than 10 minutes while other concentrations remained liquefied after the 24-hour period.
A cumulative study was conducted with samples that did form a gel consistency to
analyze the release kinetics of methylene blue. At day 0, 1 mL of phosphate buffered saline was
added to each vial. Each day of the study, 1 mL of this phosphate buffered saline and methylene
blue solution was removed and absorbance and concentration was measured using ultravioletvisible spectroscopy. This mixture was then be discarded and new phosphate buffered saline was
added to each sample until the gel had completely degraded. Samples of Pluronic F127 at 19
percent weight and above with 7.8% methylene blue proved to have the greatest longevity.
A second trial was conducted using 19-21 percent weight Pluronic F127 with 7.8%
methylene blue in 10 mL and 20 mL vials to compare the effects of surface degradation. In
comparison to the 20 mL vial, the 10 mL vial showed significant increase in longevity. Increased
concentrations of Pluronic F127
Of the samples analyzed, 21 percent weight Pluronic F127 and 7.8% methylene blue
proved to be the most clinically favorable sample for long-term delivery. Gel formation occurred
instantly at room temperature and degraded over a period of 7 days. This specific sample also
showed to have the highest percentage of methylene blue released during the cumulative release
study.
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Introduction
While the creation of hydrogels originated in 1894, they made their first appearance in
the medical field in 1961, with the creation of soft contact lenses. They have consistently been a
popular topic within the biomedical research community because of their biocompatible
characteristics. Within the medical community today, they have commonly been used for wound
therapy as they can mimic tissues and provide moisture to promote cell turnover (Wheeler, et al.,
1996). However, more recently they have also shown to be potential drug vehicles capable of
providing localized delivery. As compared to oral or intravenous delivery, this treatment method
is novel in its ability to decrease the likelihood of autoimmune responses (Milling, Zhang, &
Irvine, 2017).
Hydrogels are composed of a sophisticated hydrophilic matrix of polymers. Natural or
synthetic polymers can be used in order to achieve an appropriate level of water absorption and
longevity. These polymers are considered smart materials as they are capable of detecting and
responding to changes in their physical and chemical environment (Ahmed, 2013).
The objective of my research is to determine the most biocompatible composition of a
hydrogel composed of Pluronic F127 and Methylene Blue. This will be determined by
conducting a cumulative release study using ultraviolet-visible spectroscopy. I chose to analyze
potential medical benefits of this localized drug delivery in veterinary medicine, specifically
pertaining to methemoglobinemia in small animals.
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Literature Review
A 1% solution of methylene blue is typically administered intravenously to treat for
methemoglobanemia in both humans and animals. Dosage for dogs and cats ranges from 110mg/kg over the span of several minutes (Constable, Hinchcliff, Done, Grünberg, & Radostits,
2017). Under normal circumstances, blood gas levels in small animals consists of 0-1%
methemoglobin. Typically, oxidation of hemoglobin and reduction of methemoglobin occurs
spontaneously each day to maintain homeostasis. However, methemoglobinemia can occur when
the ferrous irons of the heme group in hemoglobin are oxidized from Fe2+ to Fe3+ and can no
longer bind to oxygen molecules. An increase in as little as 10% of blood gas levels of
methemoglobin can prevent oxygen from being released, leading to respiratory distress. At or
above 20% methemoglobin levels are considered life threatening and patients can suffer from
shock, seizures, and central cyanosis (Pharmocodynamics, n.d.).
Methemoglobinemia is typically acquired in small animals through the ingestion of
toxins, specifically NSAIDS such as acetaminophen. Because of the widespread usage of
NSAIDS, toxicosis is common is small animals. Within dogs, acute toxicosis can occur after
ingestion of 100 mg/kg of acetaminophen. However, patients may not display clinical signs until
200 mg/kg is ingested. Cats can display clinical signs of cyanosis of mucous membranes at 10-40
mg/kg. Methemoglobanemia can also be induced by the use of localized anesthetics such as
lidocaine and benzocaine (Patton, Blamer, & Horak, 2016).
An autosomal-recessive form can occur in which enzymatic reduction of methemoglobin
is depleted. Type I of this congenital form has been documented in dogs and results from a
mutation in Cytochrome B5 Type A. Affected patients may display cyanosis, hypoxia, disturbed
or absent pubertal development, and undermasculinization. Serum testing will display elevated
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levels of methemoglobin and sex steroid deficiency, decreased levels of erythrocyte cytochrome
b5, and normal levels of glucocorticoids and mineralocorticoids. Type II is characterized by a
complete loss of enzymatic activity of cytochrome b5 reductase which eventually leads to
encephalopathy, loss of motor skills, and decreased life expectancy. However, type II has not
been documented in small animals (McKenna, et al., 2014).
Methylene Blue is typically used for treatment in patients with either congenital or
acquired forms of methemoglobinemia. It acts as a cofactor to reduced nicotinamide adenine
dinucleotide phosphate (NADPH) as it is reduced by NADPH to leukomethylene blue to in turn
become an electron donor and non-enzymatically reduce methemoglobin to hemoglobin.
Methylene Blue has the potential to increase the NADPH methemoglobin reductase pathway
roughly 5-to-10 fold.
However, when administered intravenously, methylene blue can lead to hemolytic
anemia in patients with a glucose-6-phosphate dehydrogenase deficiency as it is an imperative
enzyme in the formation of NADPH and low levels prevent function of the NADPH-dependent
methemoglobin reductase pathway. Research of localized delivery of methylene blue in patients
with G6PD deficiencies has not yet been conducted (Patton, Blamer, & Horak, 2016). The
formation of Heinz bodies can be induced in cats when treated long-term with methylene blue
containing antiseptics. However, when administered intravenously at reoccurring doses for
nitrite-induced methemoglobinemia, there was no evidence to show that methylene blue caused
Heinz body formation (Rumbeiha & Oehme, 1992).
Pluronic F-127, a poloxamer, is composed of a hydrophobic polyoxypropylene chain and
two chains of hydrophilic chains of polyoxyethylene. In aqueous solutions, it assembles into
micelles that are dependent on polymer concentration and temperature. An important property of
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Pluronic F127 is its ability to be thermoreversible. Below critical micelle temperature, the triblock of polymers becomes hydrated and soluble. This critical micelle temperature occurs near
37 degrees Celsius, making it physiologically compatible. Above this critical temperature, it will
form a gel consistency and begin degradation. Pluronic F127 has surfactant properties that allow
it to interact with hydrophobic substances and biological membranes (Nie, Hsiao, Pan, & Yang,
2011). In combination with water, it has been successfully used for drug and gene delivery as
well as tissue scaffolding in stem cells and lung tissue (Cidade et al., 2019).
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Materials and Methods
Aim 1: Fabrication and Characterization of the Injectable Hydrogel Platform.
Rationale: To prepare the hydrogel, Pluronic F127 was added to deionized water in solutions of
15-21 weight percent in 20 mL vials. The Pluronic F127 polymer was allowed to dissolve under
mechanical stirring on a magnetic stir plate for 24 hours. Once this was complete, methylene blue
was added in varying concentrations of 7.8, 15.6, and 31.2 weight percent to evaluate the release
kinetics of different loading dosages. Each sample was then placed in an oven at 37 degrees
Celsius. Gelation time was determined by the amount of time it took for the solution to no longer
flow in the tube without reaching solidification.
Aim 2: Evaluate Release Kinetics of Pluronic F127-Injectable Hydrogel System
Rationale: Sample solutions were prepared as previously described with one caveat. Release
studies were conducted by measuring absorbance spectroscopy of Methylene Blue. The
absorbance curve generated by these trials were compared with a baseline absorbance curve from
Methylene Blue solution. The most efficient absorbance indicated the concentration of Methylene
Blue needed. Once this concentration was achieved, cumulative release studies were conducted to
determine release time in 24-hour time intervals.
Aim 3: Modification of Injectable Hydrogel and Re-evaluation of Release Kinetics Based on Vial
Volume
Rationale: Based on the results from previous methodology, a specific concentration of Pluronic
F127 and methylene blue was chosen to evaluate the impact of vial volume on surface degradation
and release kinetics. This was conducted by creating hydrogels as previously described within two
different vial sizes of 10 mL and 20 mL. Concentrations of Pluronic F127 and methylene blue
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were determined by longevity and absorbance values from original trials. Release studies were
again conducted using ultraviolet-visible spectroscopy.

Release Kinetics of Methylene Blue

11

Data Analysis
Figure 1. 7.8% Methylene Blue in 20 mL Vial
Percent
Weight

Day 1

Day 1

Day 2

Day 2

Day 3

Day 3

Absorbance

Concentration

Absorbance

Concentration

Absorbance

Concentration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gels

1.113

0.73

1.143

0.75

0.580

0.38

instantly at

1 mL of

0.75 mL

0.5 mL

room

hydrogel

hydrogel

hydrogel

temperature.

solution

solution

solution

with 2 mL

with 2 mL

added PBS

PBS

Gel Time

Pluronic
F127
5%

No gel
formation

10%

No gel
formation

15%

No gel
Formation

20%

Gel formation did not occur for 5-15% weight Pluronic F127. Gel formation did occur at
20% weight Pluronic F127 but an ice bath was needed to continue stirring the polymer as gel
formation occurred immediately at room temperature. The ice bath decreased the temperature of
the solution which allowed the magnetic stir bar to move freely. Complete degradation of the
20% weight gel occurred after three days.
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Figure 2. 15.6% Methylene Blue in 20 mL Vial
Percent

Gel Time

Weight

Day 1

Day 1 Concentration

Absorbance

Pluronic F127
15%

No gel formation

-

-

16%

No gel formation

-

-

17%

Gel formation after

1.349

0.89

24 hours

0.5 mL hydrogel
solution with 1.5 mL
PBS added

18%

Gel formation after 4
minutes

1.007

0.66
0.5 mL hydrogel
solution with 1.5 mL
PBS added

Gel formation did not occur at 15% or 16% Pluronic F127. While gel formation did occur
after 24 hours for 17%, this would not be a favorable gel time for clinical use. Both 17% and
18% degraded after a single day.
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Figure 3. 31.2% Methylene Blue in 20 mL Vial
Percent

Gel Time

Weight

Day 1

Day 1

Absorbance

Concentration

Pluronic F127
15%

No gel formation

-

-

16%

No gel formation

-

-

17%

Gel at 24 hours

1.341

0.88
0.5 mL hydrogel
solution and 2.5 mL
PBS added

18%

Gel at 7 minutes

1.359

0.5 mL hydrogel
solution and 3 mL
PBS added

Gel formation occurred at 17% and 18% Pluronic F127. 18% would be more clinically
relevant because of the shorter gel time of 7 minutes. However, both concentrations completely
degraded after one day.
Higher concentration of 20 percent weight Pluronic F127 and 7.8% Methylene Blue
showed slower release kinetics, so a new trial using 19, 20, and 21 percent weight Pluronic F127
was conducted with 7.8% Methylene Blue. Two separate vial sizes of 10 mL and 20 mL were
used to compare the impact of vial volume on surface degradation and release kinetics. For all
samples, gel formation occurred instantly at room temperature. Samples with Pluronic F127
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concentrations at or above 20 weight percent required an ice bath while stirring to prevent gel
formation at room temperature.
Figure 4. Calibrations Curve of Methylene Blue

Absorbance

Calibration Curve of Methylene Blue y = 604697x + 0.0318
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.00E+00 2.00E-07 4.00E-07 6.00E-07 8.00E-07 1.00E-06 1.20E-06 1.40E-06

Molarity

Figure 5. 19% Pluronic F127 and 7.8 % Methylene Blue in 20 mL Vial
Day

Absorbance

Concentration

1

1.000

0.66
1 mL hydrogel solution and 2
mL PBS added

2

0.910

0.60
1 mL hydrogel solution and 2
mL PBS added

Figure 6. Cumulative Release of 7.8% Methylene Blue with 19% Pluronic F127 in 20 mL Vial
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Percentage of Moles Released

Cumulative Release of 7.8% Methylene Blue with
19% Pluronic F127 in 20 mL Vial
3.00E+01
2.50E+01
2.00E+01
1.50E+01
1.00E+01
5.00E+00
0.00E+00
0.00E+00

5.00E-01

1.00E+00

1.50E+00

2.00E+00

2.50E+00

Days

Figure 7. 20% Pluronic F127 and 7.8 % Methylene Blue in 20 mL Vial
Day

Absorbance

Concentration

1

0.798

0.53
1 mL hydrogel solution and 4
mL PBS added

2

0.981

0.65
1 mL hydrogel solution and 5
mL PBS added
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Figure 8. Cumulative Release of 7.8% Methylene Blue with 20% Pluronic F127 in 20 mL Vial

Percentage of Moles Released

Cumulative Release of 7.8% Methylene Blue
with 20% Pluronic F127 in 20 mL Vial
60
50
40
30
20
10
0

0

0.5

1

1.5

2

2.5

Days

Figure 9. 21% Pluronic F127 and 7.8 % Methylene Blue in 20 mL Vial
Day

Absorbance

Concentration

1

0.398

0.26
1 mL hydrogel solution and 3
mL PBS added

2

0.810

0.53
1 mL hydrogel solution and 3
mL PBS added
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Figure 10. Cumulative Release of 7.8% Methylene Blue with 21% Pluronic F127 in 20 mL Vial

Percentage of Moles Released

Cumulative Release of 7.8% Methylene Blue with
21% Pluronic F127 in 20 mL Vial
25
20
15
10
5
0
0.00E+00

5.00E-01

1.00E+00

1.50E+00

2.00E+00

2.50E+00

Days

Figure 11. 19% Pluronic F127 and 7.8% Methylene Blue in 10 mL Vial
Day

Absorbance

Concentration

1

0.971

0.64
1 mL hydrogel solution with
1 mL PBS added

2

0.916

0.60
1 mL hydrogel solution with
2 mL PBS added

3

0.752

0.50
1 mL hydrogel solution with
1 mL PBS added

4

0.771

0.51
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1 mL hydrogel solution with
2 mL PBS added
5

0.697

0.46
1 mL hydrogel solution with
2 mL PBS added

6

0.933

0.62
1 mL hydrogel solution with
1 mL PBS added

7

0.768

0.51
1 mL hydrogel solution with
2 mL PBS added

Figure 12. Cumulative Release of 7.8% Methylene Blue with 19% Pluronic F127 in 10 mL Vial

Percentage of Moles Released

Cumulative Release of 7.8% Methylene Blue
with 19% Pluronic F127 in 10 mL Vial
70
60
50
40
30
20
10
0

0

1

2

3

4

Days

5

6

7

8
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Figure 13. 20% Pluronic F127 and 7.8% Methylene Blue in 10 mL Vial
Day

Absorbance

Concentration

1

0.672

0.44
1 mL of hydrogel solution with 2 mL PBS
added

2

0.957

0.63
1 mL of hydrogel solution with 2 mL PBS
added

3

0.786

0.52
1 mL of hydrogel solution with 2 mL PBS
added

4

0.838

0.55
1 mL hydrogel solution with 1 mL PBS
added

5

0.960

0.63
1 mL hydrogel solution with 1 mL PBS
added

6

0.505

0.33
1 mL hydrogel solution with 2 mL PBS
added

Figure 14. Cumulative Release of 7.8% Methylene Blue with 20% Pluronic F127 in 10 mL Vial

Percentage of Moles Released

Cumulative Release of 7.8% Methylene Blue
with 20% Pluronic F127 in 10 mL Vial
60
50
40
30
20
10
0

0

1

2

3

4

Days

5

6

7
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Figure 15. 21% Pluronic F127 with 7.8% Methylene Blue in 10 mL Vial
Day

Absorbance

Concentration

1

0.592

0.39
1 mL hydrogel solution with 4 mL PBS
added

2

0.941

0.62
1 mL hydrogel solution with 2 mL PBS
added

3

0.685

0.45
1 mL hydrogel solution with 2 mL PBS
added

4

0.638

0.42
1 mL hydrogel solution with 2 mL PBS
added

5

0.680

0.45
1 mL hydrogel solution with 2 mL
PBS added

6

0.765

0.50
1 mL hydrogel solution with 1 mL PBS
added

7

0.802

0.53
1 mL hydrogel solution with 2 mL PBS
added
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Figure 16. Cumulative Release of 7.8% Methylene Blue with 21% Pluronic F127 in 10 mL Vial

Percentage of Moles Released

Cumulative Release of 7.8% Methylene Blue with
21% Pluronic F127 in 10 mL Vial
7.00E+01
6.00E+01
5.00E+01
4.00E+01
3.00E+01
2.00E+01
1.00E+01
0.00E+00
0.00E+001.00E+002.00E+003.00E+004.00E+005.00E+006.00E+007.00E+008.00E+00

Days
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Discussion
All three solutions within the large vials degraded within two days, making them more
useful for short-term medical use. The 10 mL vials proved more relevant for long-term release as
they degraded in the span of 6-7 days. 21% Pluronic F127 with 7.8% methylene blue in a 10 mL
vial proved to be the most appropriate combination for long-term release as its degradation
period was the longest and percentage of methylene blue released was the highest at 61.1%. For
short-term use, 20% Pluronic F127 with 7.8% methylene blue in a 20 mLvial would be the most
appropriate as it released the highest percentage of methylene blue at 52.8%. Degradation of the
hydrogels was influenced by the volume of the vial in which they were created. Varying
concentrations of methylene blue showed to be insignificant in altering surface degradation time
and absorption. Manipulation of these variables was more influenced by vial size and polymer
concentration. For long-term use as in the case of congenital patients, Pluronic F127 may not be
a suitable polymer as concentrations above 21% may be difficult to solubilize.
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Conclusions and Implications
Having a single injection of the methylene blue hydrogel would make treatment more
feasible for patients requiring long-term treatment rather than maintaining a consistent intravenous
method. Concentrations of both methylene blue and Pluronic F127 can be easily manipulated in
order to achieve appropriate dosage and longevity for the specific patient. However, weight
percentages of Pluronic F127 at 19%-21% would likely be a favorable concentration in a clinical
setting as gel formation occurs instantly at body temperature. Localized delivery of methylene blue
might also create potential for patients suffering from methemoglobanemia that also have a
glucose-6-phosphate dehydrogenase deficiency as smaller amounts of NADPH might be efficient.
Methylene blue hydrogels might also be more beneficial for cats as they’re more susceptible to
Heinz body formation and hemolytic anemia. Delivering long-term, low doses could potentially
reverse the effects of methemoglobinemia without inducing life-threatening side-effects.
Moving forward, animal trials would be most appropriately conducted in large animals
such as cattle and sheep as methylene blue is more commonly used for toxicosis. Future treatment
in small animals may also be more financially effective as minimal amounts of Pluronic F127 and
methylene blue are needed. Hospitalization and IV catheter placement would also no longer be
necessary. Because of the thermoreversible properties of Pluronic F127, hydrogels could be
prepared ahead of time and stored in a refrigerator at 3 degrees Celsius without gel formation or
surface degradation. Upon being introduced into the body, the hydrogel solution would instantly
form a gel consistency and begin release of methylene blue.
Further analysis of different injection sites could also be conducted in the future to
manipulate the rate of absorption of methylene blue. Because of its biocompatible nature, a
hydrogel injectable isn’t isolated to subcutaneous delivery.
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